Compare Duke Energy Corp (DUK) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Duke Energy Corp vs Pfizer Inc — how do they compare? Duke Energy Corp trades at $116.51 (market cap $90.06B), while Pfizer Inc trades at $27.74 (market cap $159.59B). The key difference: Pfizer Inc is the larger of the two by market cap, and Pfizer Inc pays the higher dividend (6.14%). Which is the better fit depends on your goals — on Pluang, investors hold Duke Energy Corp for 74 Days and Pfizer Inc for 158 Days on average.
| DUK | PFE | |
|---|---|---|
Market Cap | $90.06B | $159.59B |
Volume | 3,988,081 | 30,937,010 |
Sector | Utilities | Health |
52-Week High | $133.46 | $29.02 |
52-Week Low | $113.23 | $23.67 |
Typical Hold Time | 74 Days | 158 Days |
Enterprise Value | $182.56B | $211.09B |
Dividend Yield | 3.76% | 6.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Duke Energy (DUK) trades at $116.84, up 1.02% on the day, with a bearish technical signal but strong fundamentals including consistent earnings beats and a 15.78% net income margin. Recent news highlights dividend stability and data center growth opportunities, though rising Treasury yields pressure utility stocks. The company maintains solid cash flow from operations of $12.33B in 2025, supporting its dividend payments.
DUK offers a balanced outlook with a consensus price target of $135.33, implying upside, but faces risks from high debt levels and interest rate sensitivity. Earnings growth and data center demand are key catalysts, while investor sentiment is mixed amid macroeconomic headwinds.
Pfizer (PFE) trades at $27.82, up 1.22% with a bullish technical signal from moving averages. The company shows stable revenue around $62-63B with consistent earnings beats in recent quarters. Analysts maintain a $29.40 consensus target with 40% buy ratings. Recent news highlights Pfizer's focus on obesity and oncology pipelines as key growth drivers.
Pfizer offers value with defensive cash flows and dividend stability, though patent cliffs and margin compression present challenges. The stock's current valuation appears reasonable relative to sector peers, with upside potential if pipeline developments succeed. Key risks include competitive pressures and regulatory hurdles for new drug approvals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Duke Energy Corp
Duke Energy is one of the largest U.S. utilities, with regulated utilities in the Carolinas, Indiana, Florida, Ohio, and Kentucky that deliver electricity to nearly 8 million customers. Its natural gas utilities serve more than 1.5 million customers. Duke operates in three major segments: electric utilities and infrastructure
Read more on DUK →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
